Literature DB >> 12867626

IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system.

M Magdalena Gherardi1, Juan C Ramírez1, Mariano Esteban1.   

Abstract

Development of a protective host response against intracellular pathogens requires innate and cell-mediated immune responses, with cytokines playing an important role in host defences. Different studies in mice have shown that IL-12 can promote protective immunity to a variety of viruses but, during virus infection, little is known about the in vivo function of IL-18 alone or in combination with IL-12. Using recombinant vaccinia viruses (rVVs) expressing IL-12 and IL-18, the antiviral role of both cytokines in mice has been analysed. The specific anti-VV immune response elicited and the persistence of the virus in target tissues were compared in BALB/c mice inoculated with rVVs expressing IL-12 and IL-18 either singly or in combination. Delivery of IL-12 and IL-18 by rVVs in mice induced a significant enhancement in virus clearance from ovaries and spleen, greater than that expected from the sum of action of both cytokines. Virus clearance involved NK and T cells, as demonstrated in mice depleted of NK cells and in immunodeficient SCID animals. Th1 parameters (CD8(+) T cell response and IgG2a : IgG1 ratios) were increased in mice inoculated with rVVs expressing both IL-12 and IL-18 as compared to those animals receiving a single cytokine. These findings indicate that when IL-12 and IL-18 are delivered by rVVs, different mechanisms involving both the innate and specific arms of the immune system act as mediators in the synergistic action of IL-12 and IL-18, leading to VV clearance. These results are of interest for the design of prophylactic as well as therapeutic VV-based strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12867626     DOI: 10.1099/vir.0.19120-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  27 in total

1.  The poxvirus A35 protein is an immunoregulator.

Authors:  Kristina E Rehm; Gwendolyn J B Jones; Alice A Tripp; Mark W Metcalf; Rachel L Roper
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 2.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

3.  MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2.

Authors:  Michael L Davies; Janet J Sei; Nicholas A Siciliano; Ren-Huan Xu; Felicia Roscoe; Luis J Sigal; Laurence C Eisenlohr; Christopher C Norbury
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

4.  Common SNPs/haplotypes in IL18R1 and IL18 genes are associated with variations in humoral immunity to smallpox vaccination in Caucasians and African Americans.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Neelam Dhiman; Richard B Kennedy; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

5.  Cytokine-Mediated Activation of NK Cells during Viral Infection.

Authors:  Bailey E Freeman; Hans-Peter Raué; Ann B Hill; Mark K Slifka
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

6.  NK cell-extrinsic IL-18 signaling is required for efficient NK-cell activation by vaccinia virus.

Authors:  Joshua D Brandstadter; Xiaopei Huang; Yiping Yang
Journal:  Eur J Immunol       Date:  2014-06-17       Impact factor: 5.532

7.  Natural Killer Cells and Innate Interferon Gamma Participate in the Host Defense against Respiratory Vaccinia Virus Infection.

Authors:  Georges Abboud; Vikas Tahiliani; Pritesh Desai; Kyle Varkoly; John Driver; Tarun E Hutchinson; Shahram Salek-Ardakani
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

8.  Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.

Authors:  Kristina E Rehm; Rachel L Roper
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

9.  Lower levels of gamma interferon expressed by a pseudotyped single-cycle simian immunodeficiency virus enhance immunogenicity in rats.

Authors:  Yue Peng; Fan-ching Lin; Paulo H Verardi; Leslie A Jones; Tilahun D Yilma
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

10.  Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.

Authors:  Andrea Worschech; Nanhai Chen; Yong A Yu; Qian Zhang; Zoltan Pos; Stephanie Weibel; Viktoria Raab; Marianna Sabatino; Alessandro Monaco; Hui Liu; Vladia Monsurró; R Mark Buller; David F Stroncek; Ena Wang; Aladar A Szalay; Francesco M Marincola
Journal:  BMC Genomics       Date:  2009-07-07       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.